To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
-
Mouse GCase Antibody
Rabbit monoclonal antibody directed against mouse GCase.
Estimated Availability: 2025
-
Human GCase Antibody
Rabbit monoclonal antibody directed against human GCase.
Estimated Availability: 2025
-
Rab 12 Antibody
Rabbit monoclonal antibody directed against human Rab 12.
Estimated Availability: Late 2024
-
TOMM20 Ubiquitinated at K56/61 Antibody
Rabbit monoclonal antibody directed against the K56/61-ubiquitinated TOMM20.
Estimated Availability: Late 2024
-
Alpha-Synuclein Ubiquitinated at K45/48/60 Antibody
Rabbit monoclonal antibody directed against the K45/48/60-ubiquitinated alpha-synuclein.
Estimated Availability: Late 2024
-
INPP5F pS940 Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine 940 of INPP5F.
Estimated Availability: Late 2024
-
Floxed Parkin Mouse*
Mice with loxP sites flanking Parkin exon 4 for conditional knockout using Cre-expressing viral vectors.
Model was generated and deposited by Dr Ted Dawson at Johns Hopkins University through the MJFF Sponsored Tools Program.
-
AAK1 pS623 Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine 623 of AAK1.
Estimated Availability: Late 2024
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic